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New Therapy Update

Celiprolol
A Unique Selective Adrenoceptor Modulator
James J. Nawarskas, PharmD,* Angela Cheng-Lai, PharmD, BCPS,† and William H. Frishman, MD‡

Abstract: Celiprolol is a β-blocker with a unique pharmacologic profile: it
is a β1-andrenoceptor antagonist with partial β2 agonist activity. Given this
combination of effects, celiprolol may be better described as a selective adrenoreceptor modulator. It has antihypertensive and antianginal properties and
is indicated for those uses in various countries around the world. In the United
States, however, the proposed indication for this drug will be for the treatment
of vascular type Ehlers–Danlos syndrome, a rare connective tissue disorder
characterized by fragile arterial structure and an increased risk of life-threatening vascular complications. By reducing heart rate and pulsatile pressure,
celiprolol may reduce the mechanical stress on collagen fibers within the
arterial wall and be of benefit in patients with vascular type Ehlers–Danlos
syndrome. The largest investigation of celiprolol in vascular Ehlers–Danlos
syndrome was prematurely terminated due to significant benefit with celiprolol in reducing arterial events in patients with this condition. Celiprolol,
therefore, represents a β-blocker that is unique from others in its class in both
its pharmacology and clinical applications.
Key Words: celiprolol, Ehlers–Danlos, β-blockers, vascular Ehlers–Danlos
syndrome, Ehlers–Danlos syndrome, Ehlers–Danlos syndrome type IV
(Cardiology in Review 2017;25: 247–253)

β

-Adrenoceptor–blocking agents (also known as β1-adrenoceptor
antagonists or β-blockers) are used to treat a variety of disorders
such as arterial hypertension, systemic hypertension, angina, coronary
heart disease, arrhythmias, hypertrophic cardiomyopathy, mitral valve
prolapse, migraine, and glaucoma.1–3 The pharmacological classification of these agents is based on their affinity, β1-selectivity, partial
agonist activity, effects on other adrenergic receptors, and physicochemical properties.1 For some conditions, the efficacy of the various
β1-adrenoceptor antagonists is similar, whereas in other conditions,
only certain subgroups have demonstrated therapeutic benefits. In the
United States, there are currently 17 β-adrenoceptor antagonists available for the treatment of cardiovascular and other disorders, although
globally there are over 30 available for clinical use (Figure 1).4 Celiprolol (3-[3-acetyl-4-(3-t-butylamino-2-hydroxypropoxy)phenyl]-2,1-diethylurea hydrochloride; Figure 2) was developed as a third-generation
β1-adrenoceptor antagonist with partial β2 agonist activity and a
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unique pharmacological profile.5 Like β blockers, it demonstrates
antihypertensive and antianginal activity; however, it lacks the typical side effects of the class, such as bronchoconstriction, depression
of left ventricular function, and peripheral vasoconstriction.5 This is
likely a result of its β2 agonist activity.2,6–9 Given this unique combination of pharmacologic effects, celiprolol is perhaps more accurately
described as a selective adrenoceptor modulator (SAM). Furthermore,
celiprolol’s ability to stimulate β2-receptors, influence vascular tone,
and directly affect smooth muscle suggests its potential usefulness in
patients with cardiovascular disease and concomitant lung disease.2,3,8
Recently, the unique properties of celiprolol have inspired investigation into its use in a rare connective tissue disorder—Ehlers–Danlos
syndrome, vascular type (vEDS; formerly known as EDS type IV).
There are 6 major types of EDS, each defined according to signs
and symptoms and thought to involve a unique connective tissue defect
(Table 1).10,11 vEDS is an autosomal dominant inherited connective tissue
disorder (100% phenotypic penetrance) caused by structural defects of
the pro α1 (III) chain of collagen type III (COL3A1) gene.12,13 Mutations
in the COL3A1 gene result in decreased thermal stability and proteolytic
processing irregularities, which subsequently lead to procollagen degradation.13 Complications of vEDS include life-threatening arterial dissections and ruptures, vascular aneurysms, intestinal ruptures, and uterine
ruptures.14 The average life span of patients with vEDS is approximately
50 years of age, with manifestation of the disorder often evident by 20
years of age.15,16 vEDS is suspected when a combination of clinical findings is present. The Villefranche criteria provide guidance on clinical
diagnosis (Table 2).14,17 The diagnosis is confirmed by the identification
of a pathogenic mutation in COL3A1 gene or the appearance of abnormal type III procollagen in cultured fibroblasts in patients with clinical
features of vEDS.15 Currently, there are no Food and Drug Administration (FDA)–approved therapies for vEDS.18 Celiprolol was investigated
for the treatment of vEDS because of the observed effects of reduced
heart rate, mean, and pulsatile pressures in animals and in patients with
hypertension and with potentially decreased continuous and pulsatile
mechanical stress on collagen fibers within the arterial wall.19 On the
basis of these data and on the fragile connective tissues associated with
vEDS, celiprolol was investigated as a preventive therapy for the lifethreatening risks, specifically arterial dissections and ruptures and intestinal and uterine ruptures associated with vEDS.

PHARMACOKINETIC PROPERTIES OF CELIPROLOL
As a whole, β1-adrenoceptor antagonists have similar therapeutic effects; however, their pharmacokinetic properties differ.19 This is
attributed to the distinct aromatic ring structure of these compounds,
which results in differences in absorption, metabolism, first-pass hepatic
metabolism, lipid solubility, protein binding, and renal clearance among
the drugs. Specifically, configuration of the asymmetric β-carbon of
the side chain determines activation or blockade effect.20 Celiprolol’s
aromatic ring structure (benzene) is similar to other β1-adrenoceptor
antagonists and is most closely related to acebutolol (Figure 2).21,22

Absorption
β1-Adrenoceptor antagonists are either considered lipophilic
or hydrophilic. Celiprolol is a hydrophilic agent, freely soluble in

Cardiology in Review • Volume 25, Number 5, September/October 2017

www.cardiologyinreview.com |

Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.

247

Cardiology in Review • Volume 25, Number 5, September/October 2017

Nawarskas et al

clinical significance in some patients.26,27 In addition, concomitant
administration of drugs such as chlorthalidone, hydrochlorothiazide,
theophylline, or digoxin may have an effect on its bioavailability.23
As a class, β1-adrenoceptor antagonists are known to interact with
several drugs, particularly with agents that affect cardiovascular
function. A list of select drug interactions with celiprolol is found
in Table 3.2,25–28

Distribution
Distribution of β1-adrenoceptor antagonists occurs rapidly
from the blood to other tissues.29 The distribution of celiprolol has
been studied in animals and humans. Celiprolol was found to be a
water-soluble substance that is widely distributed in all tissues, with
the exception of the brain, after absorption.24 This is likely due to
its hydrophilic properties.23,25,29 In vitro studies indicate that the rate
of diffusion across the human placenta is 3–4 times lower than that
of comparative β-blockers (propranolol, timolol, and labetalol) with
approximately 25% plasma protein binding (Table 4).24 It is unclear
whether this translates to a lower risk of fetal complications with
celiprolol.

Metabolism
Celiprolol is minimally metabolized, with only a very low percentage of a dose being excreted.8 Similar to other β1-adrenoceptor
antagonists, celiprolol displays first-pass metabolism. However,
the concentration of celiprolol is greatly reduced before it reaches
the systemic circulation. A small study in healthy volunteers demonstrated no drug accumulation with chronic dosing over a 7-day
period.8

Excretion
FIGURE 1. β-Adrenoceptor antagonists.4 ISA indicates intrinsic sympathomimetic activity.
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According to their pharmacokinetic properties, β1adrenoceptor drugs are divided into 2 categories: those eliminated
via hepatic metabolism and those eliminated (unchanged) via the
kidney.30 The pharmacokinetics of celiprolol have been studied in
animals and patients with primary hypertension and chronic stable
angina pectoris.24 Investigations have found that celiprolol is minimally metabolized and excreted unchanged via the urine and feces,
with a half-life of approximately 4–5 hours (10–15% observed dose
excreted in the urine).23,24 One study also reports the possible urinary
excretion of a celiprolol metabolite.7
A summary of celiprolol’s pharmacokinetic properties is
found in Table 4.8,23

PHARMACODYNAMIC PROPERTIES OF CELIPROLOL

H 3C
FIGURE 2. Celiprolol chemical structure.
water.23 Most β1-adrenoceptor antagonists (except atenolol) are
absorbed in the small intestine.1 Mean peak plasma concentrations
after oral doses of 100–600 mg of celiprolol range from 300 to 3000
µg/L.23,24 The bioavailability of celiprolol is dose-dependent: 30% at
100 mg and 70% over the range 300–400 mg.24,25 Food may impair
this bioavailability; however, the effect is not clinically relevant with
long-term therapy.23 Grapefruit juice and orange juice, both inhibitors of the organic anion–transporting polypeptide 1A2 (OATP1A2),
have been shown to cause a significant decrease in the oral absorption of celiprolol.26 Although the clinical relevance of this interaction
has not been fully assessed, studies have suggested that the effects of
celiprolol on blood pressure and heart rate are not affected. Nevertheless, the marked reduction in celiprolol bioavailability in the presence
of grapefruit or orange juice suggests that this interaction may be of
248 | www.cardiologyinreview.com

Celiprolol was developed as a third-generation β-adrenoceptor
antagonist with selective β1-antagonist, partial β2-agonist, and mild
α2-antagonist actions. The α2 antagonism is weak and ineffective
in blocking the effects of the α2 agonist clonidine. The α2 agonist
effects of celiprolol are, therefore, believed to contribute little to its
overall pharmacologic effect.23 Its blockade of β1-adrenoreceptors
reduces sympathoadrenal stimulation of the heart during physiological stress.23 In addition, celiprolol’s blockade of β1-adrenoreceptors
reduces heart rate (negative chronotropic effect) in the sinoatrial node
and decreases cardiac contractility (negative inotropic effect) in the
myocardium.23 Furthermore, studies indicate that celiprolol improves
vasodilation through β2 agonism and may also act on β3 receptors as
evidenced by a 2013 study of porcine coronary arteries, which demonstrated that celiprolol exerts β3-adrenoceptor agonistic activity with
resulting vasorelaxation.2,5,6 In addition, celiprolol may induce coronary vasodilation due to stimulation of the release of nitric oxide.31 As
a result of this activity profile, celiprolol may offer advantages over
other β-adrenergic antagonists due to its bronchosparing properties,
mild lipid effects, and minor cardiac conduction effects.2
© 2017 The Author(s). Published by Wolters Kluwer Health, Inc.

Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.

Cardiology in Review • Volume 25, Number 5, September/October 2017

TABLE 1.

Celiprolol

EDS Types

EDS Type

Distinguishing Characteristics

Hypermobile
Classical
Vascular
Kyphoscoliosis
Arthrochalasia
Dermatosparaxis

Estimated Frequency

Chronic pain and joint hypermobility that may lead to subluxations and dislocations.
Skin hyperextensibility (stretchy) and joint hypermobility. Skin is smooth, velvety,
and fragile.
Most serious of all the EDS types due to possibility of arterial or organ rupture.
Skin is usually thin and translucent, which is most apparent over the chest and
abdomen.
Joint laxity and weak muscle tone at birth with progressing scoliosis.
Congenital hip dislocation often associated with severe generalized joint
hypermobility with recurrent subluxations.
Severe skin fragility with substantial bruising. Skin is soft, doughy, and sagging.

1 in 10,000 to 15,000 people
1 in 20,000 to 40,000 people
1 in 90,000 to 250,000 people
About 60 cases reported worldwide.
About 30 cases reported worldwide.
About a dozen cases reported worldwide.

EDS indicates Ehlers–Danlos syndrome.
Data adapted from National Institutes of Health10 and Ehlers Danlos Society.11

TABLE 2.

TABLE 3.

vEDS Criteria

Major diagnostic criteria
• Arterial aneurysms, dissection, or rupture
• Intestinal rupture
• Uterine rupture during pregnancy
• Family history of vEDS
Minor diagnostic criteria
• Thin, translucent skin
• Characteristic facial appearance (thin vermilion of the lips,
micrognathia, narrow nose, and prominent eyes)
• Acrogeria (an aged appearance to the extremities, particularly the
hands)
• Carotid–cavernous sinus arteriovenous fistula
• Hypermobility of small joints
• Tendon/muscle rupture
• Early-onset varicose veins
• Pneumothorax/hemopneumothorax
• Easy bruising
• Chronic joint subluxations/dislocations
• Congenital dislocation of the hips
• Talipes equinovarus (clubfoot)
• Gingival recession
vEDS indicates vascular Ehlers–Danlos syndrome.
Data adapted from Byers and Holbrook,12 Pepin et al,15 and Oderich et al.16

Celiprolol Drug Interactions

Agent

Nature of Interaction

Chlorthalidone and
hydrochlorothiazide
Nondihydropyridine calcium
channel antagonists
Clonidine

Antidiabetic agents

Nonsteroidal anti-inflammatory
agents
Orange juice
Grapefruit juice
Itraconazole
Rifampin/rifampicin

Cardiovascular Effects

Sympathomimetic agents

Studies support the idea that celiprolol reduces arteriolar
resistance and improves blood flow without depressing cardiac function.23 In healthy adults, a single 400-mg oral dose reduced standing diastolic blood pressure by approximately 10% with no change
in systolic blood pressure.32 In patients with hypertension, celiprolol moderated the positive chronotropic effects of sympathetic
arousal, did not depress resting cardiac output, and reduced resting
total peripheral resistance.23 Regarding celiprolol’s effect on cardiac
conduction, in vivo animal studies demonstrated that treatment did
not accelerate the ventricular rate during electrically induced atrial
fibrillation despite stimulation of cardiac β2-adrenoceptors.33 Furthermore, celiprolol had no membrane stabilizing or local anesthetic
activity.25,33 In a small study of patients with stable atrial fibrillation,
the normalized maximum rate of left ventricular pressure reduction
immediately after systole (dP/dtip) increased by 24%, and the left
ventricular relaxation time constant declined by 20% after celiprolol administration.23 In addition, Vyssoulis et al34 found, in patients
with left ventricular hypertrophy, that celiprolol lowered blood pressure to normal levels and reduced left ventricular size estimated from
© 2017 The Author(s). Published by Wolters Kluwer Health, Inc.

Concomitant use of other
antihypertensive agents or
tricyclic antidepressants,
barbiturates, or phenothiazines

Coadministration reduces the
bioavailability of celiprolol
In combination with β adrenergic
antagonists, have additive effects on
cardiac conductive system
β-Adrenergic antagonists may
exacerbate the rebound hypertension,
which can follow withdrawal of
clonidine
In combination with β adrenergic
antagonists, may intensify blood
sugar–lowering effects of insulin
and antidiabetic drugs and may
mask symptoms of thyrotoxicosis or
hypoglycemia
May decrease the hypotensive effects of
β-adrenergic antagonists
Reduces the bioavailability of celiprolol
Reduces celiprolol plasma
concentrations
Almost doubles celiprolol plasma
concentrations, likely due to
increased absorption
Reduces celiprolol plasma
concentrations, likely due to reduced
absorption
Counteract the effects of β-adrenergic
antagonists
Potentiate the antihypertensive effects
of β adrenergic antagonists

Data adapted from Riddell et al25 and Lilja et al.26–28

TABLE 4.
Absorption
Plasma T1/2
Cmax
Metabolism
Excretion

Pharmacokinetic Properties of Celiprolol
30% After 100 mg; 74% After 400 mg
4–5 hours
300–3000 μg/L after oral doses of 100–600 mg
Minimal
10–15% of oral dose excreted in urine, remainder in
feces

Data adapted from Caruso et al8 and Smith and Wolf.24
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FIGURE 3. Kaplan–Meier curves of event-free survival in 53 patients with vascular Ehlers–Danlos syndrome. Primary end point
(A). Primary and secondary endpoints (B). Reprinted with permission from the study by Ong et al.43
end-systolic and diastolic diameters, interventricular septal thickness, and posterior wall thickness at end diastole and end systole.
Small studies with celiprolol in patients with heart failure have
shown variable results. In 1 study of 16 patients with reduced left
ventricular ejection fraction (LVEF), 3 months of celiprolol therapy
showed hemodynamic benefits and improved LVEF in patients with
nonischemic cardiomyopathy, but the benefits in those with ischemic
cardiomyopathy were mixed.35 A larger study of 132 patients with
reduced LVEF showed no difference between celiprolol and placebo
in the primary end point of change in functional status (measured
by the Goldman score) after 1 year of treatment.36 Some of the secondary efficacy measures showed an advantage with celiprolol (heart
rate was reduced more and DiBianco heart failure score, which is
a composite of exertional and decubitus dyspnea, asthenia, and leg
edema was reduced more), but other efficacy measures showed no
significant differences compared to placebo (LVEF, end-diastolic
diameter, fractional shortening, and exercise duration).36 In aggregate, although these small trials did not show consistent efficacy with
celiprolol for treating heart failure, they did suggest that the drug was
safe in this population.

Respiratory Effects
The effects of celiprolol on the respiratory function of healthy
patients and asthmatic patients have been studied.36 Although respiratory function in patients with asthma was not changed with single
doses of celiprolol (200 or 400 mg), bronchospasm and asthma have
been reported in nonasthmatic patients with ischemic heart disease
250 | www.cardiologyinreview.com

and hypertension being treated with celiprolol.23,37,38 Monitoring for
respiratory symptoms is, therefore, still recommended with the use
of celiprolol in both asthmatic and nonasthmatic patients.38

Metabolic Effects
Similar to α-adrenoceptor antagonists, but unlike many other
β1-adrenoceptor antagonists, celiprolol has no harmful effects on
lipid and lipoprotein profiles but may have mild beneficial effects.39
In a study of 100 patients with hypertension, celiprolol 200 mg once
daily reduced low-density lipoprotein cholesterol (LDL-C) levels in
hyperlipidemic patients (baseline LDL-C >160 mg/dL) by 16.9% and
total cholesterol by 12.8%. No significant changes were observed in
patients with baseline LDL-C levels lower than 160 mg/dL.39
In a small placebo-controlled, crossover study, celiprolol 100–
400 mg once daily did not induce significant changes in glomerular
filtration rate, renal plasma blood flow, plasma renin activity, filtration fraction, serum creatinine, aldosterone, or urinary enzymes.40

CLINICAL TRIALS
Four trials demonstrated the role of celiprolol in improving hypertension and vascular elasticity. In 1988, Donaldson et al41
evaluated the hemodynamic effects of celiprolol in a small group
(n = 10) of patients diagnosed with ischemic heart disease. Cardiac
catheterization was performed, and left ventricular pressure and aortic pressure were recorded for 30 minutes post celiprolol treatment
(intravenous infusion of 10 mg over 5 minutes). The measurements
© 2017 The Author(s). Published by Wolters Kluwer Health, Inc.
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were taken at rest, in sinus rhythm, and during atrial pacing at a rate
of 100 bpm. Results of the study demonstrated that celiprolol exerted
a vasodilatory effect without depressing cardiac function.41
A randomized, double-blind study was conducted in 2 centers over 9 months to understand the pathogenesis of the vascular
lesions of vEDS. Ninety-eight patients with essential hypertension
were treated with either 200-mg celiprolol or 10-mg enalapril.19 The
efficacy was similar in both groups and indicated that the decrease in
carotid artery internal diameter was significantly related to the reduction in pulse pressure rather than mean blood pressure.19
Roman et al42 utilized duplex echo Doppler techniques to
determine the site of celiprolol’s vasodilating effect. Thirty-five
hypertensive patients were treated with increasing doses of celiprolol, 200 and 400 mg, over 15 days. Duplex echo Doppler was used
to measure forearm (brachial artery) arterial and arteriolar vasodilation, before and during each celiprolol dose period. Celiprolol significantly (P < 0.05) increased brachial artery diameter and blood flow
velocity compared to baseline. Statistically significant (P < 0.05)
changes were also seen in forearm vascular measures: resistance
decreased and compliance increased in response to celiprolol. These
changes, except for blood flow velocity, occurred in a dose-dependent manner.42
These trials formed the backdrop for a study of celiprolol
in vEDS, a condition in which reduction of arterial wall stress and
increased vascular elasticity would likely be beneficial.

Celiprolol

In 2010, Ong et al43 demonstrated the reduction of arterial
and organ complications in patients with vEDS after treatment
with celiprolol. The Beta-Blockers in Ehlers-Danlos Syndrome
(BBEST) study was a prospective, multicenter, randomized, open
trial with blinded assessment of clinical events that evaluated
53 patients who received either celiprolol or no treatment over
a planned 5 years. The inclusion/exclusion criteria for this study
were adapted from the Villefranche diagnostic criteria as shown
in Table 2.43 Patients treated with celiprolol demonstrated a reduction in arterial events 3-fold greater than untreated patients (Figures 3 and 4).43 These results were achieved without significant
changes in heart rate or blood pressure; the reduction in events was
statistically significantly different from controls in the subset of
vEDS patients with COL3A1 mutations.43,44 In addition, celiprolol
demonstrated mild vasodilating effects in the hypertensive vEDS
patients.42

ADVERSE EFFECTS
Pooled data from clinical trials of patients with primary
hypertension and/or angina pectoris reported no difference in
adverse events between celiprolol and placebo (Figure 5).3 Additional analyses have found celiprolol to not induce clinically significant bradycardia compared to propranolol and to produce less
dizziness, fatigue, and tiredness compared to atenolol—signifying
an advantageous tolerability profile.23 Nonetheless, as with other

FIGURE 4. Kaplan–Meier curves of event-free survival in 33 patients with vascular Ehlers–Danlos syndrome with positive
COL3A1 mutation. Primary end point (A). Primary and secondary end points (B). Reprinted with permission from the study by
Ong et al.43
© 2017 The Author(s). Published by Wolters Kluwer Health, Inc.
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FIGURE 5. Most frequent adverse effects of celiprolol reported in double-blind, placebo-controlled trials (n = 2884). Reproduced with permission from the study by Lamon.3

β-blockers, celiprolol should not be used in patients with cardiogenic shock, decompensated heart failure, sick sinus syndrome,
second- or third-degree heart block, or severe bradycardia.45 Celiprolol, unlike other β-blockers, may relax bronchial smooth muscle,
rendering it theoretically safe for use in patients with pulmonary
disease.45 In fact, several studies have shown celiprolol to not
significantly affect respiratory function in patients with chronic
obstructive lung disease46,47 or asthma.48,49 However, there have
been reports of asthma and bronchospasm occurring in patients
receiving celiprolol23,38 and a case of hypersensitivity pneumonitis
occurring with celiprolol, which recurred upon rechallenge of the
drug.50 Therefore, caution should still be exercised in patients with
lung disease who are taking celiprolol, and monitoring for respiratory symptoms is still recommended even in patients without lung
disease.38

USE IN VASCULAR EHLERS–DANLOS SYNDROME
Celiprolol is approved in many countries for the treatment of
cardiovascular disorders; however, it is not yet approved in the United
States for any indication. In 2015, the FDA granted celiprolol orphan
drug status for the treatment of vEDS.51
Due to mutations in COL3A1 and abnormal vascular smooth
muscle cell signaling, patients with vEDS have high carotid wall
stress (steady or pulsatile) and are at high risk for arterial dissection and rupture.52 A reduction in the amplitude of carotid wall
stress, along with the reduction of heart rate, and dP/dt have been
suggested as potential benefits of celiprolol as preventive therapy
for vEDS.52 The clinical use of celiprolol as a preventative measure for the life-threatening arterial dissections and ruptures and
organ ruptures associated with vEDS has been suggested based
on the agent’s capacity to reduce heart rate, mean pressure, and
pulsatile pressure. Thus, celiprolol can decrease the continuous
and pulsatile mechanical stress on collagen fibers within the
arterial wall.43,51 In addition, celiprolol is thought to strengthen
the arterial wall potentially via the upregulation of collagen synthesis. Given the strong associations between β-adrenoceptors
and transforming growth factor-β (TGFβ) pathways, Ong et
al43 suggested that β2 stimulation by celiprolol could enhance
collagen synthesis via the TGFβ pathway. Moreover, Brooke44
suggested that β-adrenoceptor blockers suppress TGFβ expression, which could result in decreased matrix turnover, which
ultimately reduces the continuous mechanical stress on collagen
fibers within the vascular wall and increases the elasticity of the
radial artery.
252 | www.cardiologyinreview.com

CONCLUSIONS
In a recent publication, Thanawala et al53 recommend against
grouping all β-adrenoceptor antagonists into 1 class. The authors
discussed a 3-state model of receptor activation that correlated with
biased signaling of ligands. This was best represented when reviewing clinical data that demonstrated that not all β-adrenoceptor antagonists were effective in treating congestive heart failure.53 This further
confirms the idea that classification of β-adrenoceptor antagonists
should be founded on several factors: affinity, β1-selectivity, partial
agonist activity, and physicochemical properties.1 On the basis of
celiprolol’s unique pharmacologic profile, a β1 adrenergic antagonist with partial β2 agonist activity, reported β3-agonism, mild α2antagonism, lack of membrane-stabilizing or local anesthetic activity,
vasodilator properties, and the minimal occurrence of typical side
effects of the β-adrenergic antagonist class (eg, bronchoconstriction,
depression of left ventricular function, and peripheral vasoconstriction), one may consider labeling celiprolol as a SAM rather than as
a β-blocker. Moreover, in light of the associations reported between
β-adrenergic receptors and the TGFβ signaling cascade, investigation into celiprolol’s therapeutic efficacy via this mechanism is likely
to further contribute to management of patients with vEDS and perhaps other rare cardiovascular diseases such as Loeys–Dietz syndrome and Marfan syndrome, in which TGFβ is believed to play a
significant role in disease pathogenesis.43,54
vEDS is a rare genetic connective tissue disorder with lifethreatening complications that include arterial dissections and ruptures, and intestinal and uterine ruptures.14 Currently, there are no
FDA-approved therapies for vEDS in the United States, and physicians face the challenge of establishing an effective preventative
treatment plan for their patients.18,55 Given its good tolerability and
efficacy in a controlled, randomized clinical trial in preventing catastrophic vascular events and solid-organ ruptures, celiprolol may represent an agent with the ability to preemptively reduce the morbidity
and mortality associated with vEDS. As such, it would represent a
unique and innovative use of an agent from a class of drugs with a
well-established track record of efficacy in treating other cardiovascular conditions.
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